We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

Fintel reports that on November 7, 2024, RBC Capital downgraded their outlook for Avid Bioservices (NasdaqCM:CDMO) from ...

On Tuesday, Avid Bioservices Inc (CDMO) stock saw a decline, ending the day at $12.23 which represents a decrease of $-0.02 or -0.16% from the prior close of $12.25. The stock opened at $12.25 and ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

According to Avid's CFO, as revenue increases, incremental EBITDA is expected to drop through at an ~50% rate, which is not adequately captured in the transaction price.

The $12.50-per-share takeover has been approved by Avid's board and is scheduled to close in the first quarter of 2025, ...

Avid Bioservices Inc., a Tustin-based biotech company, agreed to go private in an $850-million deal that values the company ...

Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, ...